|Targets||Checkpoint Kinase (Chk)|
|Description||The dihydrochloride salt form of LY2606368 which also known as prexasertib, is an inhibitor of checkpoint kinase 1 and has potential effect in antineoplastic. It is still under Phase II clinical trial against breast cancer and some other sorts of cancers.|
|Synonyms||UNII-9RFT476U2L; 9RFT476U2L; LY2606368 (dihydrochloride); 1234015-54-3; HY-18174A; CS-3507|
|Solubility||43mg/ml in DMSO|
|Application||The dihydrochloride salt form of LY2606368 which also known as prexasertib, is an inhibitor of checkpoint kinase 1 and has potential effect in antineoplastic.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Eli Lilly/National Cancer Institute (USA)|
SCH900776 S-isomer is the S-isomer form of SCH900776, which is a potent, selective and orally bioavailable inhibitor of checkpoint kinase Chk1. It can be used a...
CHIR-124 is a quinolone-based small molecule Chk1 inhibitor, that is structurally unrelated to other known inhibitors of Chk1. It potently and selectively inhib...
CCT 241533 dihydrochloride is a potent Chk2 inhibitor (IC50 = 3 nM) displaying >63-fold selectivity for Chk1 over Chk2 and a panel of 84 other kinases. CCT 2415...
AZD 7762 hydrochloride
AZD 7762 hydrochloride is the hydrochloride salt of AZD 7762, which is a selective and potent ATP-competitive inhibitor of Chk1 and Chk2 with IC50 values of 5 n...
CCT241533, a Chk2 inhibitor, has been found to improve the effect of genotoxic cancer therapies. IC50: 3 nM.
Prexasertib, also known as LY2606368, is an ATP-competitive CHK1 inhibitor (Ki= 0.9 nmol/L), with minor activity against CHK2 and RSK with IC50= 8 nM and 9 nM r...
CCT245737, a nitrogen heterocycle compound, has been found to be a CHK1 inhibitor that could probable be effective in antineoplastic studies. It is still under ...
3,3'-Diindolylmethane is an activator of checkpoint kinase 2 (Chk2) that induces G2/M cell cycle arrest in various cancer cell lines. It is used as an antineopl...
BML-277 is a selective APT-competitive inhibitor of the DNA damage response signaling enzyme CHK2 ( IC50 =15 nM).
This active molecular is an selective Checkpoint kinase 1 (Chk1) inhibitors and it enhances gemcitabine efficacy in tumor xenograft models. GDC-0425 was safe an...
PF-477736 is a proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits...
SCH900776, also known as MK-8776. is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activit...
CCT245737 is an orally bioactive CHK1 inhibitor (IC50 of 1.4 nM), displaying >1,000-fold selectivity against CHK2 and CDK1. It potently inhibits cellular CHK1 a...
TCS 2312 is a potent checkpoint kinase 1 (chk1) inhibitor (Ki = 0.38 nM, EC50 = 60 nM). TCS 2312 potentiates the cell killing activity of Gemcitabine in breast ...
LY2603618 is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to ente...
NSC 109555 ditosylate
NSC-109555 Ditosylate is an ATP-competitive Chk2 inhibitor with IC50 value of 0.2 μM. It acts by inhibiting histone H1 phosphorylation and attenuating mitochond...
AZD-7762 is a synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, whic...
LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.
An inhibitor of CHK1 and CHK2
CCT241533 (hydrochloride) is the hydrochloride salt form of CCT241533. As a potent Chk2 inhibitor, CCT241533 blocked CHK2 activity in human tumor cell lines in ...